Physician profile

Eileen P Smith

Dermatology · Walla Walla, WA

NPI 1558340554

$49,264.29

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$656.77

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $30,862.95 2019-2024 Skyrizi
Novartis Pharmaceuticals Corporation $12,414.42 2019-2023
Pfizer INC. $2,879.13 2019-2022
Ucb, INC. $1,707.08 2019
Lilly USA, LLC $474.69 2019-2023 Olumiant, Taltz
Celgene Corporation $175.70 2019
Janssen Biotech, INC. $140.08 2022-2023 Tremfya
Dermavant Sciences, INC. $138.97 2023-2024 Vtama
Incyte Corporation $119.57 2023 Opzelura
Ortho Dermatologics, A Division of Bausch Health US, LLC $98.17 2019
Galderma Laboratories, L.P. $80.63 2019
Genzyme Corporation $36.46 2019
Sun Pharmaceutical Industries INC. $28.64 2019-2020
Almirall LLC $24.99 2022
Biofrontera INC. $19.15 2019
Show all 19 companies
CompanyGeneral paymentsYearsTop products
E.R. Squibb & Sons, L.L.C. $16.80 2022
Amgen INC. $16.45 2023 Otezla
Leo Pharma INC. $16.41 2021
Regeneron Healthcare Solutions, INC. $14.00 2020

3 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$200.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Eileen P Smith

$49,264.29

in general payments reported 2019-2025

Years
2019-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/252114/eileen-p-smith

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.